Glen Eagle Advisors’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $59.9K | Hold |
663
| – | – | 0.01% | 417 |
|
|
2025
Q4 | $59.6K | Hold |
663
| – | – | 0.01% | 412 |
|
|
2025
Q3 | $65.3K | Buy |
663
+267
| +67% | +$26.5K | 0.01% | 405 |
|
|
2025
Q2 | $36.1K | Hold |
396
| – | – | 0.01% | 468 |
|
|
2025
Q1 | $44.8K | Hold |
396
| – | – | 0.01% | 429 |
|
|
2024
Q4 | $41.8K | Sell |
396
-30
| -7% | -$3.22K | 0.01% | 445 |
|
|
2024
Q3 | $46K | Hold |
426
| – | – | 0.01% | 434 |
|
|
2024
Q2 | $46.2K | Hold |
426
| – | – | 0.01% | 410 |
|
|
2024
Q1 | $56.2K | Sell |
426
-1
| -0.2% | -$125 | 0.01% | 389 |
|
|
2023
Q4 | $52K | Hold |
427
| – | – | 0.01% | 384 |
|
|
2023
Q3 | $47.9K | Buy |
427
+30
| +8% | +$3.81K | 0.01% | 384 |
|
|
2023
Q2 | $57.8K | Hold |
397
| – | – | 0.01% | 360 |
|
|
2023
Q1 | $51.3K | Hold |
397
| – | – | 0.01% | 367 |
|
|
2022
Q4 | $50.6K | Hold |
397
| – | – | 0.01% | 356 |
|
|
2022
Q3 | $41.5K | Hold |
397
| – | – | 0.01% | 374 |
|
|
2022
Q2 | $41.7K | Hold |
397
| – | – | 0.01% | 393 |
|
|
2022
Q1 | $50.8K | Sell |
397
-12
| -3% | -$1.45K | 0.01% | 374 |
|
|
2021
Q4 | $50.4K | Hold |
409
| – | – | 0.01% | 371 |
|
|
2021
Q3 | $58.1K | Hold |
409
| – | – | 0.02% | 353 |
|
|
2021
Q2 | $63.8K | Hold |
409
| – | – | 0.02% | 333 |
|
|
2021
Q1 | $63.6K | Hold |
409
| – | – | 0.02% | 309 |
|
|
2020
Q4 | $61.2K | Buy |
409
+1
| +0.2% | +$141 | 0.02% | 300 |
|
|
2020
Q3 | $53.9K | Hold |
408
| – | – | 0.02% | 296 |
|
|
2020
Q2 | $47.3K | Buy |
408
+2
| +0.5% | +$230 | 0.02% | 294 |
|
|
2020
Q1 | $39.8K | Hold |
406
| – | – | 0.03% | 289 |
|
|
2019
Q4 | $59K | Buy |
406
+103
| +34% | +$14.2K | 0.03% | 295 |
|
|
2019
Q3 | $40.4K | Hold |
303
| – | – | 0.03% | 309 |
|
|
2019
Q2 | $34.6K | Hold |
303
| – | – | 0.02% | 321 |
|
|
2019
Q1 | $37.5K | Hold |
303
| – | – | 0.03% | 298 |
|
|
2018
Q4 | $30.5K | Hold |
303
| – | – | 0.03% | 305 |
|
|
2018
Q3 | $38.7K | Hold |
303
| – | – | 0.03% | 299 |
|
|
2018
Q2 | $32.8K | Hold |
303
| – | – | 0.03% | 300 |
|
|
2018
Q1 | $32.1K | Hold |
303
| – | – | 0.03% | 291 |
|
|
2017
Q4 | $35.5K | Hold |
303
| – | – | 0.03% | 280 |
|
|
2017
Q3 | $34.4K | Buy |
303
+89
| +42% | +$10.3K | 0.03% | 274 |
|
|
2017
Q2 | $26.7K | Hold |
214
| – | – | 0.02% | 275 |
|
|
2017
Q1 | $25.4K | Hold |
214
| – | – | 0.02% | 264 |
|
|
2016
Q4 | $21.5K | Buy |
+214
| New | +$22.9K | 0.02% | 274 |
|
Other funds holding ZBH
VCM
VPM
Glen Eagle Advisors's ZBH Position: Q1 2026 in Review
Glen Eagle Advisors held its Zimmer Biomet (ZBH) position steady in Q1 2026 at 663 shares worth $59.9K. The position accounts for 0.01% of the portfolio, ranked #417.
Glen Eagle Advisors first reported a position in ZBH in Q4 2016 and has held it in 38 quarters since. The position peaked at $65.3K in Q3 2025. 912 funds tracked by Wall St. Rank hold ZBH as of Q1 2026.
- Glen Eagle Advisors held 663 shares of Zimmer Biomet worth $59.9K as of Q1 2026.
- Glen Eagle Advisors left its Zimmer Biomet share count unchanged in Q1 2026.
- Zimmer Biomet made up 0.01% of Glen Eagle Advisors's portfolio in Q1 2026, its #417 holding.
- Glen Eagle Advisors first reported a position in Zimmer Biomet in Q4 2016 and has held it in 38 quarters since.
- Glen Eagle Advisors's Zimmer Biomet position peaked at $65.3K in Q3 2025.
- 912 funds tracked by Wall St. Rank held Zimmer Biomet as of Q1 2026.
Based on Glen Eagle Advisors's 13F filing for Q1 2026, filed 15 May 2026.